Encompass Health Corporation (NYSE:EHC) Receives $144.17 Consensus Target Price from Brokerages

Shares of Encompass Health Corporation (NYSE:EHC) have received an average recommendation of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $144.1667.

EHC has been the subject of several research analyst reports. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Barclays cut their price target on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 5th.

Insider Transactions at Encompass Health

In related news, Treasurer Edmund Fay sold 11,937 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $107.00, for a total value of $1,277,259.00. Following the sale, the treasurer owned 89,325 shares in the company, valued at $9,557,775. This represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Patrick William Tuer sold 682 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the completion of the transaction, the executive vice president owned 24,755 shares in the company, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.80% of the company’s stock.

Institutional Trading of Encompass Health

Large investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans raised its position in Encompass Health by 57.8% during the third quarter. Thrivent Financial for Lutherans now owns 1,194,859 shares of the company’s stock valued at $151,544,000 after acquiring an additional 437,464 shares in the last quarter. Jennison Associates LLC boosted its position in Encompass Health by 12.8% in the 3rd quarter. Jennison Associates LLC now owns 894,511 shares of the company’s stock worth $113,621,000 after purchasing an additional 101,274 shares in the last quarter. AlphaCore Capital LLC acquired a new stake in shares of Encompass Health during the 4th quarter worth approximately $4,881,000. Tudor Investment Corp ET AL increased its holdings in shares of Encompass Health by 155.3% during the 3rd quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock valued at $26,765,000 after purchasing an additional 128,191 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Encompass Health by 5.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock valued at $179,141,000 after purchasing an additional 70,387 shares during the period. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Stock Down 1.5%

Encompass Health stock opened at $104.37 on Friday. Encompass Health has a 1-year low of $92.77 and a 1-year high of $127.99. The business has a fifty day moving average price of $102.77 and a 200-day moving average price of $105.82. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.17 and a quick ratio of 1.17. The stock has a market capitalization of $10.35 billion, a price-to-earnings ratio of 17.42, a PEG ratio of 2.31 and a beta of 0.72.

Encompass Health (NYSE:EHC) last announced its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.09. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities research analysts forecast that Encompass Health will post 5.96 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s dividend payout ratio is presently 12.69%.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.